Veristat agreed to buy Certara’s regulatory and medical writing business for up to $135 million, aiming to broaden services for pharma and biotech clients. Veristat said the deal will add more than 200 specialists and is supported by WindRose Health Investors. Veristat also stated it plans back-office integration without disrupting project timelines.